Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01509287 · ClinicalTrials.gov registry record
Metabolic Screening in Patients With Donnai-Barrow Syndrome
A clinical trial of Donnai-Barrow Syndrome, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 78
- Enrollment target
- 1
- Study location
NCT01509287: Completed study of Donnai-Barrow Syndrome, sponsored by Massachusetts General Hospital.
NCT01509287 is a study of Donnai-Barrow Syndrome that has completed, run by Massachusetts General Hospital. The registered enrollment target is 78 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01509287, a study of Donnai-Barrow Syndrome, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 78 participants
- Enrollment target
- 1
- Study location
Study Summary
This study focuses on the genetics and metabolism of Donnai-Barrow Syndrome (DBS).
Conditions Studied
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2010-03 |
| Est. Completion | 2022-06-30 |
What the finished NCT01509287 record still lists
NCT01509287 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 78 participants, a relatively small participant target.
The record links to 1 condition, with Donnai-Barrow Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT01509287 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01509287 about?
NCT01509287 is a clinical study titled "Metabolic Screening in Patients With Donnai-Barrow Syndrome". This study focuses on the genetics and metabolism of Donnai-Barrow Syndrome (DBS).
What is the current status of trial NCT01509287?
This trial is currently completed. The enrollment target is 78 participants. The study started on 2010-03. Estimated completion is 2022-06-30.
What conditions does trial NCT01509287 study?
This clinical trial studies the following conditions: Donnai-Barrow Syndrome.
Who is sponsoring clinical trial NCT01509287?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01509287 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia